Existing evidence has identified epigenetic alterations as the driver of immune escape (Gomez et al., 2020), so targeting epigenetic molecules such as SETDB1 may enhance the immune response and overcome immune checkpoint blockade (ICB) resistance in HCC cells. Here, SETDB1 is linked to hepatocellular carcinoma.